Sanofi Wins Injunction In Sun IP Suit Over Eloxatin
Sanofi-Aventis LLC won a preliminary injunction barring Sun Pharmaceuticals Industries Ltd. from selling a generic version of Sanofi's colon cancer drug Eloxatin, after an agreement between the parties to temporarily halt...To view the full article, register now.
Already a subscriber? Click here to view full article